La prescription de méthylphénidate associée aux antipsychotiques atypiques en pédopsychiatrie : revue de la littérature
Volume 94, numéro 2, Février 2018
[1]Spencer T.J., Biederman J., Mick E. Attention-Deficit/Hyperactivity Disorder : Diagnosis, Lifespan, Comorbidities, and Neurobiology. J Pediatr Psychol. 2007;32:631-642.
[2]Welniarz B. Le traitement de l’hyperactivité : autour de la prescription de psychostimulants. Perspect Psy. 2004;43:65-71.
[3]Benarous X., Raffin M., Milhiet V. Dysrégulation émotionnelle et comportementale sévère : une nouvelle entité pour des enfants irritables ? Neuropsychiatr Enfance Adolesc. 2014;62:72-82.
[4]Waxmonsky J., Pelham W.E., Gnagy E. The Efficacy and Tolerability of Methylphenidate and Behavior Modification in Children with Attention-Deficit/Hyperactivity Disorder and Severe Mood Dysregulation. J Child Adolesc Psychopharmacol. 2008;18:573-588.
[5]The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
[6]Biederman J. Attention-Deficit/Hyperactivity Disorder: A Selective Overview. Biol Psychiatry. 2005;57:1215-1220.
[7]Biederman J., Faraone S., Mick E. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry. 1996;35:997-1008.
[8]Pliszka S. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894-921.
[9]Rowles B.M., Findling R.L. Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. Dev Disabil Res Rev. 2010;16:273-282.
[10]Galanter C.A., Leibenluft E. Frontiers between attention deficit hyperactivity disorder and bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2008;17:325-346.
[11]Masi L., Guilé J.-M., Mille C. Dysrégulation émotionnelle et comportementale sévère chez l’enfant : évolution nosologique et affiliation aux pathologies de l’humeur. Neuropsychiatr Enfance Adolesc. 2014;62:65-71.
[12]Connor D.F., Glatt S.J., Lopez I.D., Jackson D., Melloni R.H. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41:253-261.
[13]Aman M.G., De Smedt G., Derivan A. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159:1337-1346.
[14]Lemmon M.E., Gregas M., Jeste S.S. Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. J Child Neurol. 2011;26:428-432.
[15]Pandina G.J., Aman M.G., Findling R.L. Risperidone in the Management of Disruptive Behavior Disorders. J Child Adolesc Psychopharmacol. 2006;16:379-392.
[16]Kutcher S., Aman M., Brooks S.J. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs) : clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14:11-28.
[17]Pliszka S.R., Crismon M.L., Hughes C.W. The Texas Children's Medication Algorithm Project : revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642-657.
[18]Armenteros J.L., Lewis J.E., Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder : a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46:558-565.
[19]Arnold L.E., Gadow K.D., Farmer C.A. Comorbid anxiety and social avoidance in treatment of severe childhood aggression : response to adding risperidone to stimulant and parent training ; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol. 2015;25:203-212.
[20]Bramble D.J., Cosgrove P.V.F. Parental Assessments of the Efficacy of Risperidone in Attention Deficit Hyperactivity Disorder. Clin Child Psychol Psychiatry. 2002;7:225-233.
[21]Greenhill L.L., Pliszka S., Dulcan M.K. Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S.
[22]Kronenberger W.G., Giauque A.L., Lafata D.E. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression : a prospective, open-label study. Adolesc Psychopharmacol. 2007;17:334-347. J Child
[23]Aman M.G., Binder C., Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14:243-254.
[24]Snyder R., Turgay A., Aman M. Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41:1026-1036.
[25]Correia Filho A.G., Bodanese R., Silva T.L. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry. 2005;44:748-755.
[26]Geller B., Luby J.L., Joshi P. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012;69:515-528.
[27]Biederman J., Hammerness P., Doyle R. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. 2008;4:203-207.
[28]Zeni C.P., Tramontina S., Ketzer C.R., Pheula G.F., Rohde L.A. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. Adolesc Psychopharmacol. 2009;19:553-561. J Child
[29]Findling R.L., Short E.J., Leskovec T. Aripiprazole in children with attention-deficit/hyperactivity disorder. Adolesc Psychopharmacol. 2008;18:347-354. J Child
[30]Frazier J.A., Meyer M.C., Biederman J. Risperidone Treatment for Juvenile Bipolar Disorder: A Retrospective Chart Review. J Am Acad Child Adolesc Psychiatry. 1999;38:960-965.
[31]Javelot H., Glay-Ribau C., Ligier F. Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases. Ann Pharm Fr. 2014;72:164-177.
[32]Penzner J.B., Dudas M., Saito E. Lack of Effect of Stimulant Combination with Second-Generation Antipsychotics on Weight Gain, Metabolic Changes, Prolactin Levels, and Sedation in Youth with Clinically Relevant Aggression or Oppositionality. Adolesc Psychopharmacol. 2009;19:563-573. J Child
[33]Weiss M., Panagiotopoulos C., Giles L. A Naturalistic Study of Predictors and Risks of Atypical Antipsychotic Use in an Attention-Deficit/Hyperactivity Disorder Clinic. Adolesc Psychopharmacol. 2009;19:575-582. J Child
[34]Calarge C.A., Acion L., Kuperman S., Tansey M., Schlechte J.A. e Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents. Adolesc Psychopharmacol. 2009;19:101-109. J Child
[35]Nahshoni E., Spitzer S., Berant M. QT Interval and Dispersion in Very Young Children Treated with Antipsychotic Drugs: A Retrospective Chart Review. Adolesc Psychopharmacol. 2007;17:187-194. J Child
[36]Connor D.F., Benjamin S., Ozbayrak K.R. Neuroleptic Withdrawal Dyskinesia Exacerbated by Ongoing Stimulant Treatment. J Am Acad Child Adolesc Psychiatry. 1995;34:1490-1494.
[37]Feeney D.J., Klykylo W. Risperidone and tardive dyskinesia. J Am Acad Child Adolesc Psychiatry. 1996;35:1421-1422.
[38]Benjamin E., Salek S. Stimulant-atypical antipsychotic interaction and acute dystonia. J Am Acad Child Adolesc Psychiatry. 2005;44:510-512.
[39]McLaren J.L., Cauble S., Barnett R.J. Aripiprazole induced acute dystonia after discontinuation of a stimulant medication. J Clin Psychopharmacol. 2010;30:77-78.
[40]Hollis C.P., Thompson A. Acute Dyskinesia on Starting Methylphenidate After Risperidone Withdrawal. Pediatr Neurol. 2007;37:287-288.
[41]Sabuncuoglu O. Risperidone-to-methylphenidate switch reaction in children: three cases. J Psychopharmacol (Oxf). 2007;21:216-219.
[42]Sharp B., Perdue C. Abnormal motor movements associated with combining psychostimulants and atypical antipsychotics in children. CNS Spectr. 2007;12:659-662.
[43]Sikirica V., Pliszka S.R., Betts K.A. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manag Care Pharm JMCP. 2012;18:676-689.
[44]Del Campo N., Chamberlain S.R., Sahakian B.J., Robbins T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69:e145-e157.
[45]Yanofski J. The dopamine dilemma: using stimulants and antipsychotics concurrently. Psychiatry Edgmont Pa Townsh. 2010;7:18-23.
[46]Stahl S.M., Muntner N., Lemoine P. Psychopharmacologie essentielle : bases neuroscientifiques et applications pratiques. Paris: Lavoisier Médecine sciences; 2015.